AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
"There is a significant unmet need for effective and well-tolerated agents in the treatment of both atherosclerosis and lipid modulation," said Thomas W. Gardner, Chairman and Chief Executive Officer of AtheroNova. "Based on AHRO-001's preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile. We look forward to assessing AHRO-001 in human trials and are extremely pleased to have met a significant milestone with transitioning into a clinical stage company."
The Phase 1 study is a randomized, double-blind, placebo controlled study that assesses ascending doses of AHRO-001 in healthy adult volunteers. The program advanced into Phase 1 clinical testing following extensive successful preclinical studies with AHRO-001.
"This is clearly an exciting and transformative time for us," remarked Mark K. Wedel, MD, Chief Medical Officer of AtheroNova.
Cognitive behavioral therapy shows promise for prolonged grief disorder